Advances in Management of Dermatofibrosarcoma Protuberans

Dermatologic Clinics

Volumn 29, Issue 2, 2011, Pages 191-200

  Johnson Jahangir, Hillary ^a   Ratner, Désirée ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Complete circumferential peripheral and deep margin assessment; Dermatofibrosarcoma protuberans; Mohs micrographic surgery; Platelet derived growth factor; Skin sarcoma; Targeted therapy; Wide local excision

Indexed keywords

IMATINIB;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER STAGING; CARCINOGENESIS; CHEMOSURGERY; CHROMOSOME ABERRATION; CLINICAL FEATURE; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; METASTASIS POTENTIAL; MOHS MICROGRAPHIC SURGERY; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK REDUCTION; SKIN EXAMINATION; UNSPECIFIED SIDE EFFECT; WIDE EXCISION;

DERMATOFIBROSARCOMA; HUMANS; MOHS SURGERY; SOFT TISSUE NEOPLASMS;

EID: 79952746403     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2011.02.003     Document Type: Review

References (74)

1. Mori T., Misago N., Yamamoto O., et al. Expression of nestin in dermatofibrosarcoma protuberans in comparison to dermatofibroma. J Dermatol 2008, 35(7):419-425.
2. Criscione V.D., Weinstock M.A. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007, 56(6):968-973.
3. Love W.E., Keiler S.A., Tamburro J.E., et al. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol 2009, 61(6):1014-1023.
4. Mendenhall W.M., Zlotecki R.A., Scarborough M.T. Dermatofibrosarcoma protuberans. Cancer 2004, 101(11):2503-2508.
5. Elgart G.W., Hanly A., Busso M., et al. Bednar tumor (pigmented dermatofibrosarcoma protuberans) occurring in a site of prior immunization: immunochemical findings and therapy. J Am Acad Dermatol 1999, 40:315-317.
6. Parlette L.E., Smith C.K., Germain L.M., et al. Accelerated growth of dermatofibrosarcoma protuberans during pregnancy. J Am Acad Dermatol 1999, 41:778-783.
7. Har-Shai Y., Govrin-Yehudain J., Ullmann Y., et al. Dermatofibrosarcoma protuberans appearing during pregnancy. Ann Plast Surg 1993, 31(1):91-93.
8. Gloster H.M. Dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35:355-374. [quiz: 375-6].
9. Weinstein J.M., Drolet B.A., Esterly N.B., et al. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol 2003, 139(2):207-211.
10. Maire G., Fraitag S., Galmiche L., et al. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 2007, 143(2):203-210.
11. Ugurel S., Kortmann R.D., Mohr P., et al. J Dtsch Dermatol Ges 2008, 6(Suppl 1):S17-S18.
12. Enneking Spanier W.F.S.S., Goodman M.A. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 1980, (153):106-120.
13. Mentzel T., Beham A., Katenkamp D., et al. Fibrosarcomatous (high-grade) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998, 22(5):576-587.
14. Rutgers E.J., Kroon B.B., Albus-Lutter C.E., et al. Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992, 18(3):241-248.
15. Lindner N.J., Scarborough M.T., Powell G.J., et al. Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 1999, 25(4):392-397.
16. Taylor H.B., Helwig E.B. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer 1962, 15:717-725.
17. Ohtani N., Fukusato T., Tezuka F. Sarcomatous dermatofibrosarcoma protuberans metastasized to the lung: preservation of CD34 expression in tumor cells. Pathol Int 1998, 48(12):989-993.
18. Zelger B.W., Ofner D., Zelger B.G. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans. Histopathology 1995, 26(6):519-527.
19. Zelger B., Sidoroff A., Stanzl U., et al. Deep penetrating dermatofibroma versus dermatofibrosarcoma protuberans. A clinicopathologic comparison. Am J Surg Pathol 1994, 18(7):677-686.
20. Korkolis D.P., Liapakis I.E., Vassilopoulos P.P. Dermatofibrosarcoma protuberans: clinicopathological aspects of an unusual cutaneous tumor. Anticancer Res 2007, 27(3B):1631-1634.
21. Calonje E., Fletcher C.D. Myoid differentiation in dermatofibrosarcoma protuberans and its fibrosarcomatous variant: clinicopathologic analysis of 5 cases. J Cutan Pathol 1996, 23(1):30-36.
22. Frierson H.F., Cooper P.H. Myxoid variant of dermatofibrosarcoma protuberans. Am J Surg Pathol 1983, 7(5):445-450.
23. Reimann J.D., Fletcher C.D. Myxoid dermatofibrosarcoma protuberans: a rare variant analyzed in a series of 23 cases. Am J Surg Pathol 2007, 31(9):1371-1377.
24. Mentzel T., Scharer L., Kazakov D.V., et al. Myxoid dermatofibrosarcoma protuberans: clinicopathologic, immunohistochemical, and molecular analysis of eight cases. Am J Dermatopathol 2007, 29(5):443-448.
25. Shmookler B.M., Enzinger F.M., Weiss S.W. Giant cell fibroblastoma. A juvenile form of dermatofibrosarcoma protuberans. Cancer 1989, 64(10):2154-2161.
26. Macarenco R.S., Zamolyi R., Franco M.F., et al. Genomic gains of COL1A1-PDFGB occur in the histologic evolution of giant cell fibroblastoma into dermatofibrosarcoma protuberans. Genes Chromosomes Cancer 2008, 47(3):260-265.
27. Kovarik C.L., Hsu M.Y., Cockerell C.J. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm. J Cutan Pathol 2004, 31(7):492-496.
28. Sellheyer K., Nelson P., Krahl D. Dermatofibrosarcoma protuberans: a tumour of nestin-positive cutaneous mesenchymal stem cells?. Br J Dermatol 2009, 161(6):1317-1322.
29. Patel K.U., Szabo S.S., Hernandez V.S., et al. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008, 39(2):184-193.
30. Bridge J.A., Neff J.R., Sandberg A.A. Cytogenetic analysis of dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990, 49(2):199-202.
31. Mandahl N., Heim S., Willen H., et al. Supernumerary ring chromosome as the sole cytogenetic abnormality in a dermatofibrosarcoma protuberans. Cancer Genet Cytogenet 1990, 49(2):273-275.
32. Sirvent N., Maire G., Pedeutour F. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003, 37(1):1-19.
33. Pedeutour F., Coindre J.M., Sozzi G., et al. Supernumerary ring chromosomes containing chromosome 17 sequences. A specific feature of dermatofibrosarcoma protuberans?. Cancer Genet Cytogenet 1994, 76(1):1-9.
34. Naeem R., Lux M.L., Huang S.F., et al. Ring chromosomes in dermatofibrosarcoma protuberans are composed of interspersed sequences from chromosomes 17 and 22. Am J Pathol 1995, 147(6):1553-1558.
35. Shimizu A., O'Brien K.P., Sjoblom T., et al. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res 1999, 59(15):3719-3723.
36. Llombart B., Sanmartin O., Lopez-Guerrero J.A., et al. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology 2009, 54(7):860-872.
37. Miller S.J., Alam M., Andersen J., et al. Dermatofibrosarcoma protuberans. J Natl Compr Canc Netw 2007, 5(5):550-555.
38. Miller S.J., Alam M., Andersen J., et al. The NCCN dermatofibrosarcoma protuberans guidelines, version 1 Available at:, Accessed September 1, 2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
39. Bowne W.B., Antonescu C.R., Leung D.H., et al. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000, 88(12):2711-2720.
40. Thornton S.L., Reid J., Papay F.A., et al. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol 2005, 53(1):76-83.
41. DuBay D., Cimmino V., Lowe L., et al. Low recurrence rate after surgery for dermatofibrosarcoma protuberans: a multidisciplinary approach from a single institution. Cancer 2004, 100(5):1008-1016.
42. Farma J.M., Ammori J.B., Zager J.S., et al. Dermatofibrosarcoma protuberans: how wide should we resect?. Ann Surg Oncol 2010, 17(8):2112-2118.
43. Ratner D., Thomas C.O., Johnson T.M., et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997, 37(4):600-613.
44. Gloster H.M., Harris K.R., Roenigk R.K. A comparison between Mohs micrographic surgery and wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 1996, 35(1):82-87.
45. Snow S.N., Gordon E.M., Larson P.O., et al. Dermatofibrosarcoma protuberans: a report on 29 patients treated by Mohs micrographic surgery with long-term follow-up and review of the literature. Cancer 2004, 101(1):28-38.
46. Hancox J.G., Kelley B., Greenway H.T. Treatment of dermatofibroma sarcoma protuberans using modified Mohs micrographic surgery: no recurrences and smaller defects. Dermatol Surg 2008, 34(6):780-784.
47. Wacker J., Khan-Durani B., Hartschuh W. Modified Mohs micrographic surgery in the therapy of dermatofibrosarcoma protuberans: analysis of 22 patients. Ann Surg Oncol 2004, 11(4):438-444.
48. Loss L., Zeitouni N.C. Management of scalp dermatofibrosarcoma protuberans. Dermatol Surg 2005, 31:1428-1433.
49. Rapini R.P. Comparison of methods for checking surgical margins. J Am Acad Dermatol 1990, 23:288-294.
50. Dagan R., Morris C.G., Zlotecki R.A., et al. Radiotherapy in the treatment of dermatofibrosarcoma protuberans. Am J Clin Oncol 2005, 28(6):537-539.
51. Heuvel S.T., Suurmeijer A., Pras E., et al. Dermatofibrosarcoma protuberans: recurrence is related to the adequacy of surgical margins. Eur J Surg Oncol 2010, 36(1):89-94.
52. Sun L.M., Wang C.J., Huang C.C., et al. Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 2000, 57(2):175-181.
53. Ballo M.T., Zagarts G.K., Pisters P., et al. The role of radiation therapy in the management of dermatofibrosarcoma protuberans. Int J Radiat Oncol Biol Phys 1998, 40(4):823-827.
54. Haas R.L., Keus R.B., Loftus B.M., et al. The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer 1997, 33(7):1055-1060.
55. Suit H., Spiro I., Mankin H.J., et al. Radiation in management of patients with dermatofibrosarcoma protuberans. J Clin Oncol 1996, 14(8):2365-2369.
56. Mark R.J., Bailet J.W., Tran L.M., et al. Dermatofibrosarcoma protuberans of the head and neck. A report of 16 cases. Arch Otolaryngol Head Neck Surg 1993, 119(8):891-896.
57. Marks L.B., Suit H.D., Rosenberg A.E., et al. Dermatofibrosarcoma protuberans treated with radiation therapy. Int J Radiat Oncol Biol Phys 1989, 17(2):379-384.
58. Capdeville R., Silberman S. Imatinib: a targeted clinical drug development. Semin Hematol 2003, 40:15-20.
59. Lemm D., Mügge L.O., Mentzel T., et al. Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009, 135(5):653-665.
60. McArthur G.A. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease. J Natl Compr Canc Netw 2007, 5(5):557-562.
61. McArthur G. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol 2007, 14(10):2876-2886.
62. Abrams T.A., Schuetze S.M. Targeted therapy for dermatofibrosarcoma protuberans. Curr Oncol Rep 2006, 8(4):291-296.
63. Rutkowski P., Van Glabbeke M., Rankin C.J., et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28(10):1772-1779.
64. Food and Drug Administration. Gleevec (Imatinib Mesylate) questions and answers Available at:, Accessed September 1, 2010. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm110502.htm.
65. Han A., Chen E.H., Niedt G., et al. Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009, 145(7):792-796.
66. McArthur G.A., Demetri G.D., van Oosterom A., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005, 23(4):866-873.
67. Mehrany K., Swanson N.A., Heinrich M.C., et al. Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006, 32(3):456-459.
68. Wright T.I., Petersen J.E. Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007, 33(6):741-744.
69. Lemm D., Muegge L.O., Hoeffken K., et al. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans-a case report. Oral Maxillofac Surg 2008, 12(4):209-213.
70. Mattox A.K., Mehta A.I., Grossi P.M., et al. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. J Neurosurg 2010, 112(5):965-977.
71. Sciot R., Debiec-Rychter M. GIST under imatinib therapy. Semin Diagn Pathol 2006, 23(2):84-90.
72. Thomison J., McCarter M., McClain D., et al. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate. J Cutan Pathol 2008, 35(11):1003-1006.
73. Maki R.G., Awan R.A., Dixon R.H., et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100(6):623-626.
74. Haycox C.L., Odland P.B., Olbricht S.M., et al. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 1997, 37(3 Pt 1):438-444.